Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple
AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a
AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with
Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving
Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a
MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.